Drug Discovery and Treatment of an Emerging Pandemic Infection Covid-19

Abstract

In the last decades, two serious coronaviruses have appeared in humans and animals, SARS-CoV (severe acute respiratory syndrome) and MERS-CoV (middle east respiratory syndrome) are also contagious viruses that causes ARDS stands for acute respiratory distress syndrome. SARS-CoV in 2003 and MERS-CoV in 2012 are characterized as a high mortality rate. This novel human respiratory coronaviruses, also known as SARS n-CoV or SARS-CoV-2, are needed to rapidly provide therapeutic options to reduce and prevent the spread of this outbreak. For such infections, there are currently no scientifically approved precautions or anti -viral products authorized.; therefore, effective remedial and preventive strategies have to be developed that can be easily applied to this newly emerging epidemic. In addition to all these, some therapeutic options are also being evaluated that are used for Covid-19, which includes inhibitory virus molecules or molecules that target specific replication and transcription enzymes. Since the drugs remdesivir, lopinavir-ritonavir, favipiravir, camostat mesylate, chloroquine, and hydroxychloroquine were originate closely stand high successful in controlling infection, Covid-19 looks promising. The research on Covid-19, discuss the efficacy of the several drug and vaccines against Covid-19 and previous outbreaks of SARS and MERS, and provide recommendations for new modes of treatment, assessment, and clinical research on such terrible epidemic. This paper will summarize and discuss the main biological characteristics of SARS-CoV-2 and the current scenario of emerging Covid-19 infections, as well as explain the current therapeutic medications treating Covid-19, based on the clinical trial data.